Your browser doesn't support javascript.
loading
Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR.
Vizoso, Miguel; Ferreira, Humberto J; Lopez-Serra, Paula; Carmona, F Javier; Martínez-Cardús, Anna; Girotti, Maria Romina; Villanueva, Alberto; Guil, Sonia; Moutinho, Catia; Liz, Julia; Portela, Anna; Heyn, Holger; Moran, Sebastian; Vidal, August; Martinez-Iniesta, Maria; Manzano, Jose L; Fernandez-Figueras, Maria Teresa; Elez, Elena; Muñoz-Couselo, Eva; Botella-Estrada, Rafael; Berrocal, Alfonso; Pontén, Fredrik; Oord, Joost van den; Gallagher, William M; Frederick, Dennie T; Flaherty, Keith T; McDermott, Ultan; Lorigan, Paul; Marais, Richard; Esteller, Manel.
  • Vizoso M; Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Catalonia, Spain.
  • Ferreira HJ; Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Catalonia, Spain.
  • Lopez-Serra P; Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Catalonia, Spain.
  • Carmona FJ; Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Catalonia, Spain.
  • Martínez-Cardús A; Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Catalonia, Spain.
  • Girotti MR; Molecular Oncology Group, Cancer Research UK Manchester Institute, Manchester, UK.
  • Villanueva A; Translational Research Laboratory, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Catalonia, Spain.
  • Guil S; Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Catalonia, Spain.
  • Moutinho C; Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Catalonia, Spain.
  • Liz J; Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Catalonia, Spain.
  • Portela A; Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Catalonia, Spain.
  • Heyn H; Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Catalonia, Spain.
  • Moran S; Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Catalonia, Spain.
  • Vidal A; Department of Pathological Anatomy, Bellvitge University Hospital, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Catalonia, Spain.
  • Martinez-Iniesta M; Translational Research Laboratory, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Catalonia, Spain.
  • Manzano JL; Medical Oncology Service, Catalan Institute of Oncology, Germans Trias i Pujol University Hospital, Badalona, Catalonia, Spain.
  • Fernandez-Figueras MT; Pathology Department, Germans Trias i Pujol University Hospital, Badalona, Catalonia, Spain.
  • Elez E; Medical Oncology Service, Vall d'Hebron University Hospital, Barcelona, Catalonia, Spain.
  • Muñoz-Couselo E; Medical Oncology Service, Vall d'Hebron University Hospital, Barcelona, Catalonia, Spain.
  • Botella-Estrada R; Dermatology Service, Hospital La Fe, Universidad de Valencia, Valencia, Spain.
  • Berrocal A; Medical Oncology Service, Hospital General, Valencia, Spain.
  • Pontén F; Department of Pathology, University Hospital of Uppsala, Uppsala, Sweden.
  • Oord Jv; Translational Cell &Tissue Pathology, Katholieke Universiteit Leuven, Leuven, Belgium.
  • Gallagher WM; University College Dublin School of Biomolecular and Biomedical Science, University College Dublin Conway Institute, University College Dublin, Belfield, Dublin, Ireland.
  • Frederick DT; Center for Melanoma, Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
  • Flaherty KT; Center for Melanoma, Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
  • McDermott U; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK.
  • Lorigan P; University of Manchester, Christie National Health Service Foundation Trust, Manchester, UK.
  • Marais R; Molecular Oncology Group, Cancer Research UK Manchester Institute, Manchester, UK.
  • Esteller M; 1] Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Catalonia, Spain. [2] Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Catalonia, Spain. [3] Institucio Catalana de Recerca i Estudis Avançats,
Nat Med ; 21(7): 741-50, 2015 Jul.
Article en En | MEDLINE | ID: mdl-26030178
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Progresión de la Enfermedad / Proteínas Activadoras de GTPasa / Epigénesis Genética / Receptores ErbB / Melanoma Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Año: 2015 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Progresión de la Enfermedad / Proteínas Activadoras de GTPasa / Epigénesis Genética / Receptores ErbB / Melanoma Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Año: 2015 Tipo del documento: Article